CLDN18 and neoplasm: The NetMHCpan 4.0 was used to predict potential peptides derived from three CLDN18-ARHGAP fusion types previously reported to be present in tumor samples, including junctions of CLDN18 (exon 5)-ARHGAP26 (exon 12), CLDN18 (exon 5)-ARHGAP26 (exon 10) and CLDN18 (exon 5)-ARHGAP6 (exon 2) (Table 1; Appendix Tables S1 and  S2).